Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms

Lakshmipriya Thandiyekkal Rajan, Johannes Hofland, Eskeatnaf Mulugeta, Wouter W de Herder

Open source

DOI
10.1093/ejendo/lvag135
Published
2026-08-01
Container
European Journal of Endocrinology
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ejendo/lvag135,
  title = {Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms},
  author = {Lakshmipriya Thandiyekkal Rajan and Johannes Hofland and Eskeatnaf Mulugeta and Wouter W de Herder},
  year = {2026},
  journal = {European Journal of Endocrinology},
  doi = {10.1093/ejendo/lvag135},
  url = {https://doi.org/10.1093/ejendo/lvag135}
}

RIS

TY  - JOUR
TI  - Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms
AU  - Lakshmipriya Thandiyekkal Rajan
AU  - Johannes Hofland
AU  - Eskeatnaf Mulugeta
AU  - Wouter W de Herder
PY  - 2026
JO  - European Journal of Endocrinology
DO  - 10.1093/ejendo/lvag135
UR  - https://doi.org/10.1093/ejendo/lvag135
ER  - 

APA

Rajan, L. T., Hofland, J., Mulugeta, E., & Herder, W. W. D. (2026). Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvag135

Source records